Spyre Therapeutics, Inc.
SYRE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001636282
In the last 90 days, Spyre Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 265 institutions reported holding it in 13F filings for Q2 2026, worth $8.52B in total; no superinvestor holds it.
Superinvestors holding SYRE, Q2 2026
No superinvestor reported holding SYRE in Q2 2026.
Moves by quarter
Superinvestors that opened, added to, trimmed or sold out of SYRE each quarter, comparing shares with the quarter before. A superinvestor that didn't file for a quarter isn't listed, and isn't counted as selling.
Q2 2025
0 superinvestors holding at quarter end
- Sold out
- Soros Fund Management
Q1 2025
1 superinvestor holding at quarter end
- Reduced
- Soros Fund Management (−50.0%)
Q4 2024
1 superinvestor holding at quarter end
- Added
- Soros Fund Management (+72.4%)
Q2 2024
1 superinvestor holding at quarter end
- Added
- Soros Fund Management (+382.7%)
Q1 2024
1 superinvestor holding at quarter end